Partner Headlines - THRX

  1. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  2. Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung ...

    GuruFocus
  3. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  4. Barron's Recap: Ready To Wear?

    Benzinga
  5. UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds ...

    Benzinga
  6. UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends ...

    Benzinga
  7. Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, ...

    Benzinga
  8. UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

    Benzinga
  9. Benzinga's Top Downgrades

    Benzinga
  10. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies ...

    Benzinga
  11. Theravance Announces Positive Results From a Phase 2 Study of ...

    Benzinga
  12. Theravance Announces Initiation of Phase 2b Study With TD-42 ...

    Benzinga
  13. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  14. Morgan Stanley Expects Theravance to Continue to Underperform ...

    Benzinga
  15. Top 2013 Drug Approvals: Pharma Stocks

    YCharts
  16. Positive data for asthma drug

    IBD
  17. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD
  18. Seth Klarman Buys Micron Technology, Theravance, PBF Energy, ...

    GuruFocus
  19. GlaxoSmithKline

    IBD
  20. US Stock Futures Signal Flat Start On Wall Street

    Benzinga
  21. Relvar Ellipta Approved in Japan for Treatment of Asthma

    Benzinga
  22. Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

    Benzinga
  23. Glaxo, Theravance Confirms FDA Panel Has Recommended Approval ...

    Benzinga
  24. Theravance Reports Results from Phase 2B Study 0091 with TD-42 ...

    Benzinga
  25. Missed Klarman’s 47% Gainer? His Other Value Pick

    YCharts
  26. Seth Klarman's Top 5 Second Quarter Holdings

    GuruFocus
  27. Perrigo-Elan Merger Creates Unlikely Pharma Union

    IBD
  28. UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of ...

    Benzinga
  29. Theravance to Offer $250 Million Convertible Subordinated Notes ...

    Benzinga
  30. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  31. Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

    Benzinga
  32. Theravance Offers FDA Briefing Documents for Panel Meeting on ...

    Benzinga
  33. Theravance Enters Agreement With Alfa Wassermann Worth Up To ...

    Benzinga
  34. The Baupost Group's Favorite Stocks

    Benzinga
  35. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 24,682 ...

    GuruFocus
  36. GSK and Theravance Announce Completion of the Phase III Programme ...

    Benzinga
  37. Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX

    GuruFocus
  38. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 60, ...

    GuruFocus
  39. Theravance Inc. (THRX) CEO Rick E Winningham sells 75,749 Shares

    GuruFocus
  40. A Peek Into The Market Before The Trading Starts

    Benzinga
  41. GSK and Theravance Announce Regulatory Submissions for FF/VI ...

    Benzinga
  42. Target, Amgen Among Stocks Hitting 52-Week Highs Wednesday

    FoxBusiness
  43. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  44. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
  45. Health Care Sector Wrap

    FoxBusiness
  46. Health Care Sector Wrap

    FoxBusiness
  47. GSK and Theravance Announce Positive Results From Four Pivotal ...

    Benzinga
  48. Theravance Inc. Reports Operating Results (10-K)

    GuruFocus
  49. UPDATE: Morgan Stanley Initiates Underweight, $12 PT on Theravance

    Benzinga
  50. Morgan Stanley Initiates Theravance at Underweight

    Benzinga
  51. Afternoon Movers; Markets Moved Higher

    Benzinga
  52. Morning Market Losers

    Benzinga
  53. From Earlier: GSK and Theravance Announce Initial Outcomes From ...

    Benzinga
  54. UPDATE: Piper Jaffray Raises Price Target on Theravance to $35

    Benzinga
  55. Piper Jaffray Raises PT on Theravance to $35

    Benzinga
  56. Notable Put Options Activity in Theravance

    Benzinga
  57. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 10, ...

    GuruFocus
Trading Center